Showing 3191-3200 of 4108 results for "".
- CeraVe Launches Hyaluronic Acid Serum, Line of Products for Diabetic Skinhttps://practicaldermatology.com/news/cerave-launches-hyaluronic-acid-serum-line-of-products-for-diabetic-skin/2457497/L'Oréal’s CeraVe is rolling out a Hydrating Hyaluronic Acid Serum and a Diabetics' Dry Skin Relief line, which includes a Moisturizing Cream, Hand and Foot Cream and a Cleansing Wash. Hitting shelves in late 2018, the Diabetics'
- Sinclair Pharma: Acquisition by Huadong Medicine Company Limited Now Completehttps://practicaldermatology.com/news/sinclair-pharma-acquisition-by-huadong-medicine-company-limited-now-complete/2457500/Huadong Medicine Company Limited (HMC) has acquired Sinclair Pharma Limited, a global aesthetics company headquartered in London, UK, in a deal worth approximately $222 million. HMC is a well-known Chinese pharmaceutical listed company that has established a leading aesthetics business in China a
- Ortho Dermatologics Gears Up to Launch Bryhali Lotion for Plaque Psoriasishttps://practicaldermatology.com/news/ortho-dermatologics-gears-up-to-launch-bryhali-lotion-for-plaque-psoriasis/2457514/Ortho Dermatologics expects to start distribution of Bryhali (halobetsasol propionate) Lotion, 0.01%, to U.S. wholesale pharmaceutical distributors later this month. The company received final approval from the U.S. Food and Drug Administration (FDA) for Bryhali Lotion on Nov. 6, 201
- Endo's CCH Improves Appearance of Cellulite in Buttockshttps://practicaldermatology.com/news/endos-cch-improves-appearance-of-cellulite-in-buttocks/2457516/Endo International plc’s clostridium histolyticum (CCH) performed well in two identical Phase 3 studies for the treatment of cellulite in the buttocks. Subjects receiving CCH showed highly statistically significant levels of improvement in the appearance of cellulite with treatment,
- November is Hyperhidrosis Awareness Monthhttps://practicaldermatology.com/news/november-is-hyperhidrosis-awareness-month/2457519/November is Hyperhidrosis Awareness Month. The International Hyperhidrosis Society (IHhS) wants the world to know that hyperhidrosis’ (Hh) uncontrollable, no-fault sweating can soak through clothing and water-damage electronics. This makes
- Ortho Dermatologics' Altreno Now Available in the UShttps://practicaldermatology.com/news/ortho-dermatologics-altreno-now-available-in-the-us/2457526/Ortho Dermatologics launched Altreno (tretinoin) Lotion, 0.05% for the topical treatment of acne vulgaris in patients 9 years of age and older. Altreno Lotion is the first and only tretinoin available in a lotion for acne. Altreno Lotion has been shown to be effective and generally well-tolerated
- New AD Estimate: As Many As 16.5 Million Adults Have ADhttps://practicaldermatology.com/news/new-ad-estimate-as-many-as-165-million-adults-have-ad/2457524/As many as 16.5 million adults in America have atopic dermatitis (AD). This estimate comes from a new study from the Perelman School of Medicine at the University of Pennsylvania, which also projected 6.6 million of these adults have disease that wo
- Pennsylvania Passes SUNucate, Allowing Sunscreen Use and Protective Clothing at Schoolhttps://practicaldermatology.com/news/pennsylvania-passes-sunucate-allowing-sunscreen-use-and-protective-clothing-at-school/2457529/Pennsylvania became the 17th state to allow children to possess and apply sunscreen at school. Governor Tom Wolf approved HB 1228, a piece of legislation based on American Society for Dermatologic Surgery Association’s (ASDA) model bill known as SUNucate<
- Milestone Alert: Galderma's ASPIRE Rewards Program Hits the Million Member Markhttps://practicaldermatology.com/news/milestone-alert-galdermas-aspire-rewards-program-hits-the-million-member-mark/2457530/Galderma Laboratories, L.P’s ASPIRE Rewards program has reached the one million member milestone. ASPIRE is a loyalty program for consumers and aesthetic providers who use Galderma aesthetic injectab
- Ilumya Now Available for Moderate-to-Severe Plaque Psoriasishttps://practicaldermatology.com/news/ilumya-now-available-for-moderate-to-severe-plaque-psoriasis/2457534/Ilumya™ (tildrakizumab-asmn) 100mg/mL from Sun Pharmaceutical Industries Ltd. is now available in the United States. Ilumya is an injectable interleukin-23 (IL-23) inhibitor approved by the FDA for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for s